Item 7.01 Regulation FD Disclosure

On January 18, 2022, Moleculin Biotech, Inc. (the "Company"), issued a press release to announce that it has received an updated independent safety review of certain preliminary data for the first 30 patients in its three Phase 1 clinical trials with Annamycin targeting relapsed or refractory acute myeloid leukemia (AML) and the metastases of soft tissue sarcoma to the lungs (STS Lung), which concluded there was no evidence of cardiotoxicity.

A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.





(d)     Exhibits.

Exhibit No.     Description

99.1 Press Release dated January 18, 2022

104 Cover page Interactive Data File (formatted as Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses